## Appendix Table 1: ICD and CPT codes used

| Diagnosis | ICD-9 codes | ICD-10 codes |
| :---: | :---: | :---: |
| Chronic Kidney Disease (CKD) | CKD Stage 1-5: 585.1-585.5 unspecified CKD: 585.9 <br> hypertensive CKD: 403.00-404.93 <br> diabetic CKD: 249.40, 249.41, <br> 250.40, 250.41, 250.42, 250.43 | $\begin{aligned} & \text { N18.1 - N18.5 } \\ & \text { N18.9 } \\ & \text { I12.0 - I13.2 } \\ & \text { E08.21, E08.22, E08.29 } \\ & \text { E09.21, E09.22, E09.29 } \\ & \text { E10.21, E10.22, E10.29 } \\ & \text { E11.21, E11.22, E11.29 } \\ & \text { E13.21, E13.22, E13.29 } \\ & \hline \end{aligned}$ |
| Diabetes Mellitus (DM) | 249.00-250.93 | E08.0-E13.9 |
| Hypertension (HTN) | 401.0-405.99 | I10-I16.9 |
| Cardiovascular Disease (CVD) | $\begin{aligned} & 393 .-398.99 \\ & 402.00-402.91 \\ & 404.00-404.93 \\ & 410.00-429.9 \end{aligned}$ | $\begin{aligned} & \text { I05.0 - I09.9 } \\ & \mathrm{I} 11.0, \mathrm{I} 11.9 \\ & \mathrm{I} 13.0-\mathrm{I} 13.2 \\ & \mathrm{I} 20.0-\mathrm{I} 2 . \\ & \hline \end{aligned}$ |
| Peripheral Arterial Disease (PAD) | $\begin{aligned} & 440.0-440.9 \\ & 443.0-443.9 \end{aligned}$ | $\begin{aligned} & 170.0-170.92 \\ & 173.00-173.9 \end{aligned}$ |
| Stroke | 430. - 438.9 | $\begin{aligned} & \text { I60.00 - I69.998 } \\ & \text { G45.0 - G45.9 } \\ & \hline \end{aligned}$ |
| Tumors | Malignant: 140.0-209.36 <br> Benign: 209.40-239.9 | $\begin{aligned} & \text { C00.0 - C96.9 } \\ & \text { D00.00 - D49.9 } \end{aligned}$ |
| Procedure Type | CPT codes |  |
| Radiology (CT scans and interventional radiology) |  | 704917049670498 721327219372194 741757417774178 |
| Cardiology (heart catheterization and percutaneous coronary intervention) | 9292092921929249292592928 9293792938929419294392944 9345193452934539345493455 9345993460934619353093531 9356493565935669356793568 | 929299293392934 929739297892979 934569345793458 935329353393563 9357193572 |
| Endovascular (peripheral angiography, venography, and percutaneous interventions) | 36005 36010 36011 36012 36100 <br> 36215 36216 36217 36218 36221 <br> 36225 36226 36227 36228 36245 <br> 36251 36252 36253 36254 36901 <br> 36905 36906 36907 36908 36909 <br> 37187 37188 37191 37192 37193 <br> 37213 37214 37215 37216 37217 <br> 37222 37223 37224 37225 37226 <br> 37230 37231 37232 37233 37234 <br> 37238 37239 37241 37242 37243 <br> 37248 37249 37252 37253 75600 <br> 75635 75658 75705 75710 75716 <br> 75736 75741 75743 75746 75756 <br> 75825 75827 75831 75833 75840 <br> 75872 75880 75894 75898 $0234 T$ <br> $0238 T$     | 36120 36140 36200 <br> 36222 36223 36224 <br> 36246 36247 36248 <br> 36902 36903 36904 <br> 37184 37185 37186 <br> 37197 37211 37212 <br> 37218 37220 37221 <br> 37227 37228 37229 <br> 37235 37236 37237 <br> 37244 37246 37247 <br> 75605 75625 75630 <br> 75726 75731 75733 <br> 75774 75820 75822 <br> 75842 75860 75870 <br> $0235 T$ $0236 T$ $0237 T$ |


| Appendix Table 2: Patients Characteristics by CKD recognition status with lab evidence of CKD by eGFR or uACR or both criteria |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Characteristics ${ }^{\text {a }}$ | Lab Evidence of CKD | Recognition in Pt with eGFR<60 ml/min/1.73m2 only |  |  | CKD Recognition in Pts with uACR $>30 \mathrm{mg} / \mathrm{g}$ only |  |  | CKD Recognition in Pts with both eGFR+uACR criteria |  |  |
|  | $\begin{gathered} \text { Total } \\ N=92,900 \\ \hline \end{gathered}$ | $\begin{array}{\|l\|} \hline \text { Total } \\ N=67,899 \\ \hline \end{array}$ | $\begin{gathered} \text { Recognized } \\ N=29,536(43.5 \%) \end{gathered}$ | Not Recognized $N=38,363$ (56.5\%) | $\begin{gathered} \text { Total } \\ N=11,655(12.5 \%) \\ \hline \end{gathered}$ | $\begin{gathered} \text { Recognized } \\ N=2,167 \text { (18.6\%) } \\ \hline \end{gathered}$ | Not Recognized $N=9,488$ ( $85.4 \%$ ) | $\begin{gathered} \text { Total } \\ N=13,346(14.3 \%) \end{gathered}$ | $\begin{gathered} \text { Recognized } \\ N=8,883(66.6 \%) \\ \hline \end{gathered}$ | Not Recognized $N=4,463$ (33.4\%) |
| Existing Patients at start of 10/2012 ${ }^{\text {a }}$ | 70,478 | 50,798 | 22,517 (44.3\%) | 28,281 (55.7\%) | 8,596 | 1,657 (19.3\%) | 6,939 (81.7\%) | 11,084 | 7442 (67.1\%) | 3,642 (32.9\%) |
| Entered Cohort in 10/2012-09/2014 ${ }^{\text {a }}$ | 10,121 | 7,412 | 2,984 (40.3\%) | 4,428 (59.7\%) | 1,523 | 258 (16.9\%) | 1,265 (83.1\%) | 1,186 | 764 (64.4\%) | 422 (35.6\%) |
| Entered Cohort in 10/2014-09/2016 ${ }^{\text {a }}$ | 7,453 | 5,783 | 2,380 (41.2\%) | 3,403 (58.8\%) | 981 | 169 (17.2\%) | 812 (82.8\%) | 9 | 435 (63.1\%) | 254 (36.9\%) |
| Entered Cohort in10/2016-09/2018 ${ }^{\text {a }}$ | 4,848 | 3,906 | 1,655 (42.4\%) | 2,251 (57.6\%) | 555 | 83 (14.95\%) | 472 (85.05\%) | 387 | 242 (62.5\%) | 145 (37.5\%) |
| Age, Mean (sd) | 67.5 (11.3) | 68.6 (11.3) | 69.2 (11.2) | 68.1 (11.4) | 61.4 (10.9) | 60.5 (10.4) | 61.6 (11.0) | 67.6 (9.5) | 67.3 (9.6) | 68.1 (9.3) |
| Male, n (\%) | 88,514 (95.3\%) | 64,253 (94.6\%) | 28,492 (96.5\%) | 35,761 (93.2\%) | 11,237 (96.4\%) | 2,075 (95.7\%) | 9,162 (96.6\%) | 13,024 (97.6\%) | 8,703 (98.0\%) | 4,321 (96.8\%) |
| Race, n (\%) |  |  |  |  |  |  |  |  |  |  |
| Non-hispanic White | 54,302 (58.5\%) | 41,021 (60.4\%) | 17,222 (58.3\%) | 23,799 (62.0\%) | 5,685 (48.8\%) | 930 (42.9\%) | 4,744 (50.1\%) | 7,596 (56.9\%) | 4,809 (54.1\%) | 2,787 (62.5\%) |
| Non-hispanic black | 16,823 (18.1\%) | 12,950 (19.1\%) | 5,450 (18.5\%) | 7,500 (19.6\%) | 1,666 (14.3\%) | 385 (17.8\%) | 1,281 (13.5\%) | 2,207 (16.5\%) | 1,560 (17.6\%) | 647 (14.5\%) |
| Hispanics | 11,206 (12.1\%) | 6,147 (9.1\%) | 3,431 (11.6\%) | 2,716 (7.1\%) | 2,972 (25.5\%) | 596 (27.5\%) | 2,376 (25.0\%) | 2,087 (15.6\%) | 1,537 (17.3\%) | 550 (12.3\%) |
| Asian | 211 (0.2\%) | 131 (0.2\%) | 70 (0.2\%) | 61 (0.2\%) | 48 (0.4\%) | 7 (0.3\%) | 41 (0.4\%) | 32 (0.2\%) | 22 (0.3\%) | 10 (0.2\%) |
| American Indian/Pacific Islanders | 1,278 (1.4\%) | 852 (1.3\%) | 402 (1.4\%) | 450 (1.2\%) | 196 (1.7\%) | 43 (2.0\%) | 153 (1.6\%) | 230 (1.7\%) | 164 (1.9\%) | 66 (1.5\%) |
| Unknown | 8,432 (9.1\%) | 6,317 (9.3\%) | 2,733 (9.2\%) | 3,584 (9.3\%) | 1,009 (8.7\%) | 195 (9.0\%) | 814 (8.6\%) | 1,106 (8.3\%) | 736 (8.3\%) | 370 (8.3\%) |
| Multi-Race | 648 (0.7\%) | 481 (0.7\%) | 228 (0.8\%) | 253 (0.7\%) | 79 (0.7\%) | 11 (0.5\%) | 68 (0.7\%) | 88 (0.7\%) | 55 (0.6\%) | 33 (0.7\%) |
| BMI, Mean (sd) | 30.5 (6.1) | 29.9 (5.9) | 30.0 (6.0) | 29.8 (5.8) | 32.3 (6.5) | 32.3 (6.3) | 32.3 (6.5) | 31.7 (6.3) | 31.8 (6.3) | 31.5 (6.2) |
| Co-morbidities, n (\%) |  |  |  |  |  |  |  |  |  |  |
| Diabetes w/o Hypertension | 2,109 (2.3\%) | 1,428 (2.1\%) | 448 (1.5\%) | 960 (2.6\%) | 499 (4.3\%) | 59 (2.7\%) | 440 (4.6\%) | 182 (1.4\%) | 88 (1.0\%) | 94 (2.1\%) |
| Hypertension wlo diabetes | 37,774 (40.7\%) | 35,665 (52.5\%) | 13,668 (46.3\%) | 21,997 (57.3\%) | 950 (8.2\%) | 99 (4.6\%) | 851 (9.0\%) | 1,159 (8.7\%) | 774 (8.7\%) | 385 (8.6\%) |
| Both Diabetes and Hypertension | 53,017 (57.1\%) | 30,806 (45.4\%) | 15,420 (52.2\%) | 15,386 (40.1\%) | 10,206 (87.6\%) | 2,009 (92.7\%) | 8,197 (86.4\%) | 12,005 (89.9\%) | 8,021 (90.3\%) | 3,984 (89.3\%) |
| Heart disease | 56,042 (60.3\%) | 40,857 (60.2\%) | 19,487 (66.0\%) | 21,370 (55.7\%) | 5,793 (49.7\%) | 1,167 (53.9\%) | 4,626 (48.8\%) | 9,392 (70.4\%) | 6,393 (72.0\%) | 2,999 (67.2\%) |
| Peripheral arterial disease | 13,927 (15.0\%) | 9,244 (13.6\%) | 5,156 (17.5\%) | 4,088 (10.7\%) | 1,622 (13.9\%) | 361 (16.7\%) | 1,261 (13.3\%) | 3,061 (22.9\%) | 2,286 (25.7\%) | 775 (17.4\%) |
| Stroke | 17,192 (18.5\%) | 12,381 (18.2\%) | 6,219 (21.1\%) | 6,162 (16.1\%) | 1,749 (15.0\%) | 384 (17.7\%) | 1,365 (14.4\%) | 3,062 (22.9\%) | 2,144 (24.1\%) | 918 (20.6\%) |
| Tumor | 48,499 (52.2\%) | 35,983 (53.0\%) | 16,265 (55.1\%) | 19,718 (51.4\%) | 5,301 (45.5\%) | 1,054 (48.6\%) | 4,247 (44.8\%) | 7,215 (54.1\%) | 4,873 (54.9\%) | 2,342 (52.5\%) |
| Primary Care visits/yr, Mean (sd) | 4.46 (2.80) | 4.28 (2.71) | --- | --- | 4.66 (2.82) | ---- | ---- | 5.20 (3.06) | --- | ---- |
| Specialty Care visits/yr, Mean (sd) | 0.81 (1.76) | 0.78 (1.74) | --- | --- | 0.60 (1.25) | --- | --- | 1.10 (2.14) | --- |  |
| ER visit+Hospitalization/yr, Mean (sd) | 0.71 (1.60) | 0.71 (1.62) | --- | --- | 0.58 (1.37) | --- | --- | 0.83 (1.63) | --- |  |
| Elective Procedures, $\mathrm{n} / \mathrm{yr}$, Mean (sd) |  |  |  |  |  |  |  |  |  |  |
| Radiological | 0.717 (2.06) | 0.707 (2.10) | --- | --- | 0.803 (2.00) | --- | --- | 0.695 (1.90) | --- |  |
| Endovascular | 0.091 (0.58) | 0.076 (0.51) | --- | --- | 0.079 (0.49) | --- | --- | 0.180 (0.93) | --- |  |
| Cardiac | 0.098 (0.51) | 0.088 (0.48) | --- | --- | 0.075 (0.38) | --- | --- | 0.168 (0.67) | --- |  |
| Median Blood Pressure Value |  |  |  |  |  |  |  |  |  |  |
| Not diagnosed with HTN (\%) | 2,109 (2.3\%) | 1,428 (2.1\%) | --- | --- | 499 (4.3\%) | --- | --- | 182 (1.4\%) | --- |  |
| Not available (\%) | 348 (0.4\%) | 237 (0.4\%) | --- | --- | 78 (0.7\%) | --- | --- | 33 (0.3\%) | --- |  |
| <130/80 mmHg, n (\%) | 29,340 (31.6\%) | 23,203 (34.2\%) | --- | --- | 2,592 (22.2\%) | --- | --- | 3,545 (26.6\%) | --- |  |
| 130-140/80-90 mmHg, n (\%) | 48,044 (51.7\%) | 34,047 (50.1\%) | --- | --- | 6,583 (56.5\%) | --- | --- | 7,414 (55.6\%) | --- | -- |
| >140/90 mmHg, n (\%) | 13,059 (14.1\%) | 8,984 (13.2\%) | --- | --- | 1,903 (16.3\%) | --- | --- | 2,172 (16.3\%) | --- |  |
| Medications (\%) |  |  |  |  |  |  |  |  |  |  |
| ACEIIARB | 66,266 (71.3\%) | 45,192 (66.6\%) | 20,524 (69.5\%) | 24,668 (64.3\%) | 9,801 (84.1\%) | 1,940 (89.5\%) | 7,861 (82.9\%) | 11,273 (84.5\%) | 7,564 (85.2\%) | 3,709 (83.1\%) |
| Diuretics | 54,591 (58.8\%) | 38,771 (57.1\%) | 18,100 (61.3\%) | 20,671 (53.9\%) | 6,233 (53.5\%) | 1,295 (59.8\%) | 4,938 (52.0\%) | 9,587 (71.8\%) | 6,634 (74.7\%) | 2,953 (66.2\%) |
| Statin | 40,681 (43.8\%) | 28,653 (42.2\%) | 10,760 (36.4\%) | 17,893 (46.6\%) | 6,601 (56.6\%) | 1,266 (58.4\%) | 5,335 (56.2\%) | 5,427 (40.7\%) | 3,407 (38.4\%) | 2,020 (45.3\%) |
| NSAIDs | 71,467 (76.9\%) | 49,828 (73.4\%) | 22,579 (76.5\%) | 27,249 (71..0\%) | 9,945 (85.3\%) | 1,915 (88.4\%) | 8,030 (81.4\%) | 1,694 (87.6\%) | 7,865 (88.5\%) | 3,829 (85.8\%) |



